TOXIC EPIDERMAL NECROLYSIS AND CLARITHROMYCIN

Main Article Content

Nadia Khaldi
Forensic Science Laboratory, Pellegrin Hospital, University Teaching Hospital Bordeaux, France,

Alain Miras
Forensic Science Laboratory, Pellegrin Hospital, University Teaching Hospital Bordeaux, France,

Sophie Gromb
1Forensic Science Laboratory, Pellegrin Hospital, University Teaching Hospital Bordeaux, France, 2Forensic Medicine and Medical Law at the Medicine University, Bordeaux, France

Keywords

Toxic epidermal necrolysis, clarithromycin, causality, macrolide

Abstract

Toxic epidermal necrolysis almost always occurs after taking a medication. Despite spectacular clinical signs, it is mainly diagnosed with pathologic techniques. The identification of a drug as the cause for the immune related cytotoxic reaction can be difficult if the molecule is not generally known to be a classical cause of this reaction. The present study describes a female patient who rapidly developed a severe bullous skin disease after taking clarithromycin for tonsillitis. The case illustrates the process involved in attributing causality to a molecule using an established imputability assessment framework.

Abstract 158 | PDF Downloads 185

References

1. Wolkenstein P, Roujeau JC, Revuz J. Drug i n d u c e d Toxic Epidermal Necrolysis. Clinics in dermatology 1998;16:399-409
2. Roujeau JC, Stern R. Severe adverse cutaneous reactions to drugs. The New England Journal of Medicine 1994;331:1272-85.
3. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. The Lancet 2000;356:1587-91.
4. Roujeau JC. Toxidermies médicamenteuses: quelques nouveautés. Revue Française d'allergologie immunologie clinique 2002;42:71-74.
5. Paquet P. Drugs involved in Toxic Epidermal Necrolysis. Thérapie 1993;48(2):133-139.
6. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and risk of Steven-Johnson syndrome or Toxic Epidermal Necrolysis. The New England Journal of Medicine, 1995;333(24):1600-7.
7. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science
1998;282:490-492.
8. Schnyder B, Burkhart C, Schnyder-Frutig K, et al.Recognition of sulfomethoxazole and its reactive metabolites by drug-specific CD4+T cells from allergic individuals. J Immunol 2000; 164:6647-54.
9. Yawallkar N, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. Allergy Clinic Immunol 2000;106:1171-6.
10. Hans C, Paquet C, Maréchal-Courtois C. Le traitement ophtalmologique du Syndrome de Lyell. Revue Médicale de Liège, XLVIII;7-93.
11. Becker SD. Toxic epidermal necrolysis. The Lancet 1998;351:1417-20.
12. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisées en France. Thérapie 1985;40:111-118

Article Sidebar

PDF
Published
Dec 8, 2018

Article Details

How to Cite
Khaldi, N., Miras, A., & Gromb, S. (2018). TOXIC EPIDERMAL NECROLYSIS AND CLARITHROMYCIN. Journal of Population Therapeutics and Clinical Pharmacology, 12(3). https://mail.jptcp.com/index.php/jptcp/article/view/97
Issue
Vol. 12 No. 3 (2005)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles published in JPTCP  are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Khaldi, N., Miras, A., & Gromb, S. (2018). TOXIC EPIDERMAL NECROLYSIS AND CLARITHROMYCIN. Journal of Population Therapeutics and Clinical Pharmacology, 12(3). https://mail.jptcp.com/index.php/jptcp/article/view/97